Home › Castration-Resistant Prostatic Cancer › NCT07677267

A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

Real-World Characteristics, Treatment Patterns, and Outcomes Among Adults With mCRPC Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

Who can join

Ages 18 to 115 · Men

Inclusion criteria:

* Evidence of 177Lu-PSMA-617 use on or after 01 January 2021.
* Evidence of treatment with ≥1 ARPI, before 177Lu-PSMA-617.
* Evidence of treatment with ≥1 taxane, before or after 177Lu-PSMA-617.
* Diagnosis of mCRPC prior to or on the index date. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617.
* Age ≥18 years at index.

Exclusion criteria:

• None.

About the study

The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer (mCRPC) who have previously received ≥1 androgen receptor pathway inhibitor (ARPI), ≥1 taxane, and 177Lu-PSMA-617 in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.

Sponsor: Novartis Pharmaceuticals · Participants: 1,067 · Started: Jun 30, 2026

Contact the study team

• Novartis Pharmaceuticals · Phone: +41613241111

Official record on ClinicalTrials.gov — NCT07677267

Locations in the U.S.

Conditions

• Castration-Resistant Prostatic Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.